Facebook
Twitter
LinkedIn
Forward
Rheumatology Association of Iowa 8th Annual Meeting
| Registration |
|---|
Target Audience
Healthcare professionals who work in Rheumatology.
Objectives
- Identify how to screen and diagnose early interstitial lung disease in systemic sclerosis.
- Discuss the two Food and Drug Administration approved therapies for systemic sclerosis-interstitial lung disease.
- Recognize changes in federal and local policies affecting practice.
- Evaluate the potential impact of new legislation on practice and payment models and be prepared to adapt.
- Identify opportunities for state and national advocacy, legislative action and our need for representation at the state national level.
Questions
RAI Executive Office
847-517-7225
rai@wjweiser.com
| FRIDAY, FEBRUARY 25, 2022 | ||
|---|---|---|
| 5:00 pm | Welcome and Opening Remarks | |
| 5:10 pm | Advocacy Update Michael S. Brooks, MD, FACP, FACR | |
| 6:10 pm | Adjourn | |
| SATURDAY, FEBRUARY 26, 2022 | ||
|---|---|---|
| 9:00 am | Welcome and Opening Remarks | |
| 9:15 am | Keynote Lecture: Scleroderma Dinesh Khanna, MBBS, MSc | |
| 10:15 am | Break | |
| 10:45 am | Keynote Lecture: Lung Disease & Scleroderma Dinesh Khanna, MBBS, MSc Systemic sclerosis (SSc, scleroderma) is a rheumatic disease characterized by autoimmunity, vasculopathy, and fibrosis in the skin and internal organs. It has the highest case fatality of any rheumatic disease due to significant internal organ involvement. Rheumatologists need to be qualified to screen and facilitate early diagnosis and management of internal organ complications. | |
| 11:45 am | RAI Annual Business Meeting | |
| 12:30 pm | Lunch | |
| 1:30 pm | Dessert | |
| 2:00 pm | Local and Federal Advocacy Panel Brian Henderson Dennis Tibben, MPA With physicians focused on the delivery of care, is hard to keep track of legislative and regulatory developments that will ultimately impact their provision of that care. It is important to keep us as rheumatologists informed on socioeconomic activity in Washington, as well as local governments, focusing on how new initiatives will impact their patients and practice. Rheumatologists need to be aware of federal, Iowa state and local legislation and regulations related to medication access, practice management, private payer reform and administrative simplification and its impact to the success of their practice and quality of patient care. | |
| 3:30 pm | Adjourn | |
 | Michael S. Brooks, MD, FACP, FACR Dr. Brooks attended medical school at Loyola University Stitch School of Medicine and completed his internship and residency at Loyola University Affiliated Hospitals. He completed his fellowship in rheumatology at Indiana University School of Medicine. He currently practices rheumatology at the Physician’s Clinic of Iowa, P.C. in Cedar Rapids. |
Brian Henderson Brian Henderson is a director of state government affairs where he works across the country on issues related to health care that are important to physicians. | |
 | Dinesh Khanna, MBBS, MSc Dr. Khanna is Professor of Medicine and Director, University of Michigan Scleroderma Program. He holds the Frederick G.L. Huetwell Professorship in Rheumatology. Dr. Khanna has published over 450 peer-reviewed articles and book chapters. He is the Principal Investigator on National Institutes of Health and industry-sponsored clinical studies. He won the 2015 Henkry Kunkel award from the American College of Rheumatology. |
 | Dennis Tibben, MPA Dennis Tibben is the Director of External Affairs for the Iowa Medical Society.In this role, he leads policy development and advocacy efforts with the Iowa General Assembly, Congress, and Executive Branch agencies, as well as communications efforts on behalf of the Society. Prior to joining the Iowa Medical Society, Dennis served as Correspondence and Judicial Appointments Coordinator in the Iowa Governor’s Office, as well as a Legislative Assistant in the Iowa Senate. Dennis received his bachelor’s degree in Political Science, with an emphasis in American Government, from Iowa State University and his Master of Public Administration, with an emphasis in Public Policy, from Drake University. |
Accreditation Statements
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this program for a maximum of 4.50 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Des Moines University (DMU) and the Rheumatology Association of Iowa. DMU is accredited by IMS to provide continuing medical education for physicians. DMU designates this live activity for a maximum of 4.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This live activity has been reviewed and approved for 4.50 continuing education contact hour(s). Nurses must attend the entire session to receive credit. Partial session credit is prohibited and will be forfeited.
- Other: This live activity is designated for 4.50 AMA PRA Category 1 Credit(s)TM.
EDUCATIONAL GRANTS
No ineligible company provided financial support for this continuing education activity.
DISCLOSURE
The speaker(s) will disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director.
Relevant to this educational activity's content, the following individual(s) have no conflict(s) with ineligible companies to disclose.
- Michael S. Brooks, MD, FACP, FACR - Speaker
- Bogdan Cherascu, MD, MS - Activity Director, Planning Committee Member, and Moderator
- Lorene Harder - Activity Coordinator and Planning Committee Member
- Brian Henderson - Speaker
- Dennis Tibben, MPA - Speaker
Relevant to the content of this educational activity, the following individual(s) have a conflict(s) with ineligible companies to disclose. All relationships have been mitigated by the accredited provider.
- Dinesh Khanna, MBBS, MSc - Speaker
- Consultant for: AbbVie, Actelion, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, CSL Behring, Horizon Therapeutics
- Grant or Research Support: Bristol Myers Squibb Company, Horizon Therapeutics USA, Pfizer Inc.
- Intend to discuss off-label uses of the following commercial product(s)/device(s) and agrees to inform learners of such.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
Available Credit
- 4.50 AMA PRA Category 1 Credits™
- 4.50 AOA Category 2A
- 4.50 CE Contact Hour(s)
- 4.50 IBON